Lilly signs licensing deal for early-stage diabetes therapy

Eli Lilly has inked a licensing deal with Taisho Pharmaceutical for a Phase I drug for type 2 diabetes. Lilly gained marketing rights for the drug outside of China and Japan. Financial details were not disclosed.

- read this press release for more

Suggested Articles

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial. 

The purchase comes as AstraZeneca enters a 12-month period in which it plans to file for approval of about 10 assets.